focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,812.50
Bid: 1,700.00
Ask: 1,820.00
Change: 0.00 (0.00%)
Spread: 120.00 (7.059%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European stocks head for worst week since March

Fri, 23rd Jun 2023 07:42

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

EUROPEAN STOCKS HEAD FOR WORST WEEK SINCE MARCH (0638 GMT)

European futures are heading for their worst week of losses since March's banking turmoil.

Futures on the Eurostoxx are down 0.4% while Germany's DAX futures are falling 0.6%. FTSE futures are down 0.2%.

The STOXX 600 has already shed 2.6% this week as investors digested more interest rate hikes from central banks and the prospect of higher inflation for longer.

Investors are ramping up their bets on a UK recession after the Bank of England delivered a 50 bps hike on Thursday. Even so, British retail sales unexpectedly rose in May.

Meanwhile Japan's core consumer inflation exceeded forecasts in May and an index excluding fuel costs rose at the fastest annual pace in 42 years. The Fed's Powell said on Thursday the central bank would move interest rates at a "careful pace" from here.

Eyes will be on French smart label maker SES Imagotag, whose shares were suspended on Thursday after a shortselling report on its accounts that the company rejected. Italy's Eni , together with its Norwegian unit Var, agreed to buy private-equity backed Neptune Energy in a $4.9 billion deal.

GSK Plc will also be in the spotlight after the British pharmaceutical company said it reached a confidential settlement of a litigation in the United States over claims its heartburn drug Zantac caused cancer.

(Lucy Raitano)

FRAGILE MARKETS WAIT ON PMIS (0622 GMT)

A red tide swept over Asia-session screens on Friday as markets took a hot Japanese inflation reading and the Bank of England's super-sized rate hike as bad news for growth.

Japan's Nikkei looks set to snap a 10-week winning streak and the MSCI Asia ex-Japan index was poised for its worst week of the year, as rates and inflation look higher for longer.

The yen earned some reprieve, but it's shaky and at 143 to the dollar is firmly in intervention-watch territory.

Sterling had already failed to hold on to much of the boost from the Old Lady of Threadneedle Street's hawkish turn, as bond markets see the economic fallout from high rates being deleterious, and it slid further against a rising dollar on Friday.

The Aussie, a growth bellwether, is quickly unwinding a two-week rally and Aussie stocks are down 3% in three days.

The sour turn leaves markets in a delicate spot ahead of global purchasing managers' index surveys due through the day.

Softening is already broadly expected, but, in this sort of mood, any surprise could be taken badly, as solid numbers may only augur more hikes and higher rates. British retail sales figures are also due and expected to show contraction.

Chinese markets were closed on Friday for a holiday, but FTSE China futures were down almost 1% and an early-month rally on stimulus hopes has all but faded away, leaving investors feeling besieged by bad news.

In emerging markets, it's a long way to the weekend for the Turkish Lira which is crumbling as a 650 basis point rate hike on Thursday fell far short of market expectations and was seen as a sign of the political limits on monetary policy.

Key developments that could influence markets on Friday:

Europe, UK and U.S. PMIs

UK Retail Sales

(Tom Westbrook)

More News
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.